{"slideshow_credits": null, "snippet": "The trial, which was cut short, showed that Intercept Pharmaceuticals might have a treatment for a fatty liver disease.", "abstract": "Shares of Intercept Pharmaceuticals nearly quadruple to $275.87 after clinical trial suggests that drug maker might have the first effective treatment for a fatty liver disease associated with the nation\u2019s epidemic of obesity; drug, called obeticholic acid, is a treatment for nonalcoholic steatohepatitis.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/01/10/business/promising-drug-trial-lifts-stock-of-company.html", "lead_paragraph": "The trial, which was cut short, showed that Intercept Pharmaceuticals might have a treatment for a fatty liver disease.", "headline": {"main": "Promising Drug Trial Lifts Stock of Intercept", "print_headline": "Promising Drug Trial Lifts Stock Of Company"}, "_id": "52cf618038f0d8359e12cfcf", "word_count": "725", "multimedia": [], "pub_date": "2014-01-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Stocks and Bonds", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Liver", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Intercept Pharmaceuticals Inc.", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Obesity", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}